"Linking clinical tumour response to preclinical tumour models"

 
Drug Discovery Innovation Programme, Frankfurt, 29 Nov 2018
Workshop

 

15. Linking clinical tumour response to preclinical tumour models. Drug Discovery Innovation Programme (World BI), Leonardo Hotel Frankfurt City - South, Frankfurt (11/2018) PDF

Objectives

• Review the pain points in drug R&D

• Understand PK/PD rationales that are relevant to different types of biomarker data

• Evaluate preclinical tumour models and forecast clinical efficacy

• Raise awareness of The Open Project (TOP)

Lecture 1. The reason why

• Data irreproducibility crisis

• Cancer drug development attrition 

 

Lecture 2Translational oncology modelling basics: Evaluate preclinical tumour models and forecast clinical efficacy

• Pfizer 3 pillars and AstraZeneca 5Rs

• Translational oncology modelling

Case study: Qualify A2780 xenograft as a suitable ovarian carcinoma model using PK/PD modelling

Case study: Predict clinical failure with modelling of preclinical PK/PD and clinical PK

Case study: Evaluate PC-9 xenograft as an efficacy model for EGFR by modelling preclinical PK/PD and clinical PK of afatinib

Case study: Evaluate Mia PaCa2 xenograft as an efficacy model for gemcitabine using preclinical and clinical data

Lecture 3. The Open Project

• Translational oncology modelling

• Openness, transparency, meritocracy

Company registration no. 09698685

Registered in England and Wales.

14 Tytherington Park Road, Macclesfield, Cheshire, UK  SK10 2EL 

Beyond Consulting Ltd

+44-7853 073 731